Isomorphic Labs, an AI drug development company spun off from DeepMind, is negotiating about $5 billion in financing, with a valuation of about $50 billion.

Isomorphic Labs, an AI drug development company spun off from DeepMind, is negotiating about $5 billion in financing, with a valuation of about $50 billion.